Observational studyProstate cancer and prostatic diseases2025

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.

Lauren Lenz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.